Global Sickle Cell Anemia Therapeutics Market Growth (Status and Outlook) 2025-2031

Global Sickle Cell Anemia Therapeutics Market Growth (Status and Outlook) 2025-2031

The global Sickle Cell Anemia Therapeutics market size is predicted to grow from US$ 4369 million in 2025 to US$ 10800 million in 2031; it is expected to grow at a CAGR of 16.3% from 2025 to 2031.

Sickle cell disease (SCD) is a chronic, inherited blood disorder that impacts hemoglobin, a protein found in red blood cells (RBCs) that carries oxygen throughout the body. The disease is caused by a genetic mutation in the beta-chain of hemoglobin, which results in the formation of abnormal hemoglobin known as sickle hemoglobin (HbS).

Global Sickle Cell Anemia Therapeutics key players include Emmaus Medical, Addmedica, Gamida Cell, GlycoMimetics, etc.

Americas is the largest market, with a share about 55%, followed by Europe, and Middle East & Africa, both have a share over 35 percent.

In terms of product, Blood Transfusion is the largest segment, with a share over 35%. And in terms of application, the largest application is Child, followed by Adult.

LPI (LP Information)' newest research report, the “Sickle Cell Anemia Therapeutics Industry Forecast” looks at past sales and reviews total world Sickle Cell Anemia Therapeutics sales in 2024, providing a comprehensive analysis by region and market sector of projected Sickle Cell Anemia Therapeutics sales for 2025 through 2031. With Sickle Cell Anemia Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Sickle Cell Anemia Therapeutics industry.

This Insight Report provides a comprehensive analysis of the global Sickle Cell Anemia Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Sickle Cell Anemia Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Sickle Cell Anemia Therapeutics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Sickle Cell Anemia Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Sickle Cell Anemia Therapeutics.

This report presents a comprehensive overview, market shares, and growth opportunities of Sickle Cell Anemia Therapeutics market by product type, application, key players and key regions and countries.

Segmentation by Type:
Blood Transfusion
Pharmacotherapy
Bone Marrow Transplant

Segmentation by Application:
Child
Adult

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Emmaus Medical
Addmedica
Gamida Cell
GlycoMimetics
Pfizer
Novartis
Global Blood Therapeutics
Micelle BioPharma
Bluebird Bio
Prolong Pharmaceuticals
Modus Therapeutics
Sangamo Biosciences
Bioverativ
Imara
Ironwood Pharmaceuticals

Please note: The report will take approximately 2 business days to prepare and deliver.